Mike joined Sofinnova as a General Partner in 1997. He focuses mostly on clinical-stage product companies, particularly in oncology and neurology. Mike represents Sofinnova as the Chairman of Galera Therapeutics, Checkmate Pharma, Dauntless Pharmaceuticals, IntrepidaBio, and is a member of the board of directors for Aeovian Pharmaceuticals, Pionyr Immunotherapeutics, Quanta Therapeutics and Synlogic.
Before joining Sofinnova, Mike was Group Leader of Drug Delivery at Genentech (1990–97) where his focus was developing new formulations for protein and peptide therapeutics. In 1987, he was part of the founding team of Cytel; and as Director of Product Development, he was responsible for the company’s early growth which culminated in their IPO. Additionally, he was a Scientist and Project Team Leader at Syntex Research (Roche). Mike has published 90 scientific articles and books on chemistry, drug delivery and formulation-related drug development. Mike has the honor of being the first scientist from the biotechnology industry to be elected as a Fellow of the American Association of Pharmaceutical Scientists.
Mike received his Ph.D. in Physical Chemistry from the University of Toronto and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981–84). Mike was previously the Board President of AVAC (AIDS Vaccine Advocacy Coalition), a past Advisor to the Bill and Melinda Gates Foundation, a past Strategic Advisor to One World Health, and a Founding Venture Advisory Board member of the IAVI (International AIDS Vaccine Initiative) Innovation Fund. He currently serves on the Washington University Board of Trustees in St. Louis. He is also an Adjunct Professor of Pharmaceutical Chemistry at the University of Kansas, and past Editorial Board member of J. Pharm. Sci., and a past Scientific Advisor to the Controlled Release Society.